Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

In SHUTTLE, 52.3% of patients on the higher dose achieved EASI-75, a 28.7% difference vs. placebo, while 54.1% did so on the lower dose. Our government trade tracker caught Pelosi’s 169% AI winner.

AEs more commonly observed with Dupixent compared to placebo in at least 3 patients included peripheral edema (n=8 vs. n=5), arthralgia (n=5 vs. n=3), back pain (n=4 vs. n=2), blurred vision (n=4 vs.

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

The fourth and final meeting of the regular season between the Memphis Grizzlies and Phoenix Suns had a similar feel to each of the previous three. The game was intense and came down to the final ...

Like previous years, the early 2025 Samsung flagship phone series contains three models, the Galaxy S25, Galaxy S25 Plus, and the Galaxy S25 Ultra. The main difference between the three is size.

(REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid.